下一代向治疗:塔莱特雷克提尼布在融合阳性恶性瘤中的演变作用
Samiksha Mankar1, Manoj Kumbhare1, Siddhi Chandak1
1SMBT College of Pharmacy, Nandi-hills, Dhamangaon, Igatpuri, Nashik - 422403, India.
概括
塔莱特雷克提尼布是一种下一代ROS1和NTRK抑制剂,在非小细胞肺癌中显示出高疗效和中枢神经系统透. 与早期治疗相比,它提供了更好的结果和可管理的安全性概况.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 遗传学 遗传学 是一个
背景情况:
- ROS1和NTRK基因融合是某些癌症的关键驱动因素,特别是非小细胞肺癌 (NSCLC).
- 第一代氨酸激酶抑制剂 (TKI) 最初表现有希望,但在中枢神经系统 (CNS) 透和获得耐药性方面面临限制.
- 需要下一代抑制剂来克服这些挑战并改善患者的治疗结果.
研究的目的:
- 评估taletrectinib的疗效和安全性,这是一个新的ROS1和NTRK抑制剂.
- 评估taletrectinib对抗耐药突变的活性及其中枢神经系统透能力.
- 为了探索taletrectinib在NTRK融合阳性固体瘤的瘤不可知设置中的潜力.
主要方法:
- 临床前研究评估对野生类型和耐药激酶的疗效,包括中枢神经系统透.
- 临床试验 (TRUST,TRUST-II) 评估TKI-naïve和预治疗NSCLC患者的客观反应率.
- 在NTRK融合阳性固体瘤中研究taletrectinib的篮子试验.
主要成果:
- 塔莱特雷克提尼布显示出强大的临床前疗效,包括针对ROS1 G2032R突变,具有良好的中枢神经系统透和内反应.
- 临床试验报告了高客观响应率 (超过85-90%) 在TKI-naïve NSCLC和显著的活动在crizotinib预治疗的患者.
- 可接受的安全性,胃肠道和肝脏有毒性可控,神经认知副作用比洛拉提尼布少.
结论:
- 塔莱特雷克提尼布是ROS1/NTRK驱动癌症的有前途的下一代抑制剂,具有全身和内活性.
- 它克服抗药机制的能力和有利的安全概况将其定位为精密瘤学的宝贵补充.
- 目前正在进行的试验和监管审查强调了taletrectinib在治疗融合阳性癌症中的日益重要的临床意义.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
8.4K
07:42Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Published on: September 19, 2018
8.3K
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Receptor Tyrosine Kinases
17.8K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
17.8K
